Mesenchymal stromal cells (MSCs) have particular properties that allow their use as therapeutic strategies for several cell-based applications. Historically, bone marrow (BM)-MSCs are isolated by culture adherence since specific cell surface markers are yet to be developed. This original work aimed to identify and characterize isolating expanded BM-MSCs based on their aldehyde dehydrogenase (ALDH) activity known to be a hallmark of stem cells and relevant for their isolation. We thus isolated by fluorescence-activated cell sorting technology two functionally different populations of BM-MSCs depending on their ALDH activity (ALDH+ and ALDH−). Transcriptome analysis and profiling clearly demonstrated that both populations of BM-MSCs present distinct pattern of genes related to the main properties of MSCs (proliferation, response to hypoxia, angiogenesis, phenotype, stemness, multilineage, hematopoiesis, immunomodulation) in an ALDH activity dependent manner. Both BM-MSC populations look to significantly differ in terms of biological responses and functionalities. More functional analyses are needed to understand and characterize the properties of these ALDH populations. Collectively, our results highlight ALDH activity as a potential feature for isolating and segregating functional and/or competent subset of BM-MSC populations, which may account for better and more efficient therapeutic issue.
Get full access to this article
View all access options for this article.
References
1.
FriedensteinA.J., ChailakhyanR.K., LatsinikN.V., PanasyukA.F., and Keiliss-BorokI.V.Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation, 17, 331, 1974.
2.
BajadaS., MazakovaI., RichardsonJ.B., and AshammakhiN.Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Regen Med, 2, 169, 2008.
3.
da Silva MeirellesL., ChagastellesP.C., and NardiN.B.Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci, 119, 2204, 2006.
4.
DominiciM., Le BlancK., MuellerI., et al.Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8, 315, 2006.
5.
CaplanA.I.Why are MSCs therapeutic? New data: new insight. J Pathol, 217, 318, 2009.
6.
BusserH., NajarM., RaicevicG., et al.Isolation and characterization of human mesenchymal stromal cell subpopulations: comparison of bone marrow and adipose tissue. Stem Cells Dev, 24, 2142, 2015.
7.
MeirellesL.d.S., FontesA.M., CovasD.T., and CaplanA.I.Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev, 20, 419, 2009.
8.
SamsonrajR.M., RaiB., SathiyanathanP., et al.Establishing criteria for human mesenchymal stem cell potency. Stem Cells, 33, 1878, 2015.
DelormeB., RingeJ., GallayN., et al.Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood, 111, 2631, 2008.
11.
CortiS., LocatelliF., PapadimitriouD., et al.Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells, 24, 975, 2006.
12.
MaI., and AllanA.L.The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev, 7, 292, 2011.
13.
BalberA.E.Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine. Stem Cells, 29, 570, 2011.
14.
BlackW.J., StagosD., MarchittiS.A., et al.Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature. Pharmacogenet Genomics, 19, 893, 2009.
15.
MarchittiS.A., BrockerC., StagosD., and VasiliouV.Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol, 4, 697, 2008.
16.
DolleL., BestJ., EmpsenC., et al.Successful isolation of liver progenitor cells by aldehyde dehydrogenase activity in naive mice. Hepatology, 55, 540, 2012.
17.
DolleL., BoulterL., LeclercqI.A., and van GrunsvenL.A.Next generation of ALDH substrates and their potential to study maturational lineage biology in stem and progenitor cells. Am J Physiol Gastrointest Liver Physiol, 308, G573, 2015.
18.
HoA.D., WagnerW., and FrankeW.Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy, 10, 320, 2008.
19.
CaplanA.I.Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol, 213, 341, 2007.
20.
HorwitzE.M., Le BlancK., DominiciM., et al.Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy, 7, 393, 2005.
21.
BiancoP., RobeyP.G., and SimmonsP.J.Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell, 2, 313, 2008.
22.
HorwitzE.M., and KeatingA.Nonhematopoietic mesenchymal stem cells: what are they? Cytotherapy, 2, 387, 2000.
23.
BiancoP., CaoX., FrenetteP.S., et al.The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med, 19, 35, 2013.
24.
SobiesiakM., SivasubramaniyanK., HermannC., et al.The mesenchymal stem cell antigen MSCA-1 is identical to tissue non-specific alkaline phosphatase. Stem Cells Dev, 19, 669, 2010.
25.
SimmonsP.J., and Torok-StorbB.Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood, 78, 55, 1991.
26.
TsaiC.C., and HungS.C.Functional roles of pluripotency transcription factors in mesenchymal stem cells. Cell Cycle, 11, 3711, 2012.
27.
HeoJ.S., ChoiY., KimH.S., and KimH.O.Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med, 37, 115, 2016.
28.
KangC.M., KimH., SongJ.S., et al.Genetic comparison of stemness of human umbilical cord and dental pulp. Stem Cells Int, 2016, 3453890, 2016.
29.
RanD., SchubertM., PietschL., et al.Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol, 37, 1423, 2009.
30.
KreisN.N., SanhajiM., KramerA., et al.Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells. Oncogene, 29, 5591, 2010.
31.
SolozobovaV., and BlattnerC.p53 in stem cells. World J Biol Chem, 2, 202, 2011.
32.
TerziM.Y., IzmirliM., and GogebakanB.The cell fate: senescence or quiescence. Mol Biol Rep, 43, 1213, 2016.
33.
LiZ., XiangY., XiangL., et al.ALDH maintains the stemness of lung adenoma stem cells by suppressing the Notch/CDK2/CCNE pathway. PLoS One, 9, e92669, 2014.
34.
KimR.J., ParkJ.R., RohK.J., et al.High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2alpha. Cancer Lett, 333, 18, 2013.
35.
DasR., JahrH., and van OschG.J.V.M., and FarrellE.The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev, 16, 159, 2010.
36.
OhnishiS., YasudaT., KitamuraS., and NagayaN.Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells, 25, 1166, 2007.
37.
ShiraishiA., TachiK., EssidN., et al.Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells. Cancer Sci, 108, 362, 2017.
38.
KusumaG.D., AbumareeM.H., PertileM.D., et al.Mesenchymal stem/stromal cells derived from a reproductive tissue niche under oxidative stress have high aldehyde dehydrogenase activity. Stem Cell Rev, 12, 285, 2016.
39.
TaoH., HanZ., HanZ.C., and LiZ.Proangiogenic features of mesenchymal stem cells and their therapeutic applications. Stem Cells Int, 2016, 1314709, 2016.
40.
NaganoM., KimuraK., YamashitaT., et al.Hypoxia responsive mesenchymal stem cells derived from human umbilical cord blood are effective for bone repair. Stem Cells Dev, 19, 1195, 2010.
41.
CarmelietP., and JainR.K.Molecular mechanisms and clinical applications of angiogenesis. Nature, 473, 298, 2011.
42.
ShermanS.E., KuljaninM., CooperT.T., et al.High aldehyde dehydrogenase activity identifies a subset of human mesenchymal stromal cells with vascular regenerative potential. Stem Cells, 35, 1542, 2017.
43.
HassR., KasperC., BohmS., and JacobsR.Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 9, 12, 2011.
44.
NajarM., RaicevicG., JebbawiF., et al.Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett, 146, 50, 2012.
45.
YangZ.X., HanZ.B., JiY.R., et al.CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties. PLoS One, 8, e59354, 2013.
NishihiraS., OkuboN., TakahashiN., et al.High-cell density-induced VCAM1 expression inhibits the migratory ability of mesenchymal stem cells. Cell Biol Int, 35, 475, 2011.
48.
AomatsuE., ChosaN., NishihiraS., et al.Cell–cell adhesion through N-cadherin enhances VCAM-1 expression via PDGFRbeta in a ligand-independent manner in mesenchymal stem cells. Int J Mol Med, 33, 565, 2014.
49.
HarknessL., ZaherW., DitzelN., IsaA., and KassemM.CD146/MCAM defines functionality of human bone marrow stromal stem cell populations. Stem Cell Res Ther, 7, 4, 2016.
50.
EspagnolleN., GuillotonF., DeschaseauxF., et al.CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. J Cell Mol Med, 18, 104, 2014.
51.
WuC.C., LiuF.L., SytwuH.K., TsaiC.Y., and ChangD.M.CD146+ mesenchymal stem cells display greater therapeutic potential than CD146− cells for treating collagen-induced arthritis in mice. Stem Cell Res Ther, 7, 23, 2016.
52.
NajarM., RaicevicG., Fayyad-KazanH., et al.Bone marrow mesenchymal stromal cells induce proliferative, cytokinic and molecular changes during the t cell response: the importance of the IL-10/CD210 axis. Stem Cell Rev, 11, 442, 2015.
53.
VarinA., PontikoglouC., LabatE., DeschaseauxF., and SensebeL.CD200R/CD200 inhibits osteoclastogenesis: new mechanism of osteoclast control by mesenchymal stem cells in human. PLoS One, 8, e72831, 2013.
54.
PontikoglouC., LangonneA., BaM.A., et al.CD200 expression in human cultured bone marrow mesenchymal stem cells is induced by pro-osteogenic and pro-inflammatory cues. J Cell Mol Med, 20, 655, 2016.
55.
Fajardo-OrdunaG.R., MayaniH., and MontesinosJ.J.Hematopoietic support capacity of mesenchymal stem cells: biology and clinical potential. Arch Med Res, 46, 589, 2015.
56.
BriquetA., DuboisS., BekaertS., et al.Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica, 95, 47, 2010.
57.
LioznovM.V., FreibergerP., KrogerN., ZanderA.R., and FehseB.Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. Bone Marrow Transplant, 35, 909, 2005.
58.
ZhaoK., and LiuQ.The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. J Hematol Oncol, 9, 46, 2016.
59.
NajarM., RaicevicG., CrompotE., et al.The immunomodulatory potential of mesenchymal stromal cells: a story of a regulatory network. J Immunother, 39, 45, 2016.
60.
SchaferR., SpohnG., and BaerP.C.mesenchymal stem/stromal cells in regenerative medicine: can preconditioning strategies improve therapeutic efficacy? Transfus Med Hemother, 43, 256, 2016.
61.
ZhangY., WeiQ.S., DingW.B., et al.Increased microRNA-93-5p inhibits osteogenic differentiation by targeting bone morphogenetic protein-2. PLoS One, 12, e0182678, 2017.
62.
FelimbanR., YeK., TraianedesK., et al.Differentiation of stem cells from human infrapatellar fat pad: characterization of cells undergoing chondrogenesis. Tissue Eng Part A, 20, 2213, 2014.
63.
XuX., LiX., YanR., et al.Gene expression profiling of human bone marrow-derived mesenchymal stem cells during adipogenesis. Folia Histochem Cytobiol, 54, 14, 2016.
64.
ChenQ., ShouP., ZhengC., et al.Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ, 23, 1128, 2016.
65.
MosetiD., RegassaA., and KimW.K.Molecular regulation of adipogenesis and potential anti-adipogenic bioactive molecules. Int J Mol Sci, 17, pii:E124, 2016.
66.
KusumaG.D., AbumareeM.H., PerkinsA.V., BrenneckeS.P., and KalionisB.Reduced aldehyde dehydrogenase expression in preeclamptic decidual mesenchymal stem/stromal cells is restored by aldehyde dehydrogenase agonists. Sci Rep, 7, 42397, 2017.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
